Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 89-108).

Analyses of 11 new erbB transducing viruses had previously correlated differences in disease potential with deletions or truncations in sequences encoding the carboxy-terminal domain of the chicken EGF receptor. erbB sequences of two of these viruses, one inducing only erythroblastosis (AEV-5005) and the other inducing only angiosarcoma (AAV-5005), were molecularly cloned. Sequence analysis confirmed the presence of an internal deletion in AAV-5005. The deletion was found to be inframe and to have removed 177 nucleotides. The deleted sequence had encoded a region between the kinase domain and the autophosphorylation sites of the EGF receptor. To establish that the deletion was responsible for the change in disease potential two recombinant viruses were constructed. One recombinant virus (srE) contained erbB sequences from AEV-5005. The other recombinant virus (srE/A) was identical to srE except that a restriction fragment from AAV-5005 which contained the deletion was substituted for the homologous fragment of AEV-5005. The srE virus induced only erythroblastosis, while the srE/A virus induced angiosarcoma as well as erythroblastosis. This demonstrated that the deletion was sufficient to induce angiosarcoma. Metabolic labelling did not reveal any difference in the expression or processing of these proteins and both became phosphorylated in an in vitro kinase assay. The biochemical basis for the difference in disease potential of these two related proteins remains to be determined.

Gene therapy is a fast growing technology that offers treatments for genetic diseases. The method is based on introducing genetic material into a patient to replace the disease-causing gene, using a vector. This report examines the potential of some viral vectors for gene therapy, to give Bio-Works Technologies a recommendation on what the future market demands. Oncolytic viruses, vaccines and gene editing are not treated in the report as a delimitation.  Viral vectors have different biological properties and require different purification methods, making them suitable for different applications in gene therapy. In the purification of the viruses it can be challenging to obtain a high purity and large-scale manufacturing. One major drawback with most purification methods is that they are not specific to just one virus, which leads to contaminants in the solution and lower purity. The viral vectors handled in the report are the adenovirus, adeno-associated virus, gammaretrovirus, lentivirus, alpharetrovirus, foamy virus, herpes simplex virus and baculovirus. These were chosen as they are relevant vectors for gene therapy and stay within the scope of the report. Lentiviral vectors (LVs) and adeno-associated viral vectors (AAVs) will dominate the gene therapy field in the coming years. This is based on the information that the use of AAVs and LVs in clinical trials have increased in recent years, while the other vectors mentioned above have slightly decreased or show no apparent change. However, challenges still remain in the purification processes. Ligands used in affinity chromatography for purification of AAVs are effective at removing most contaminants, but cannot distinguish between empty and loaded capsids, which can induce immune response when used clinically. This is the main challenge when purifying AAVs. The empty capsids can be removed with ion exchange chromatography, which results in higher purity but also lower recovery. There is no specific purifying method for LVs, therefore a lentivirus-specific affinity ligand, such as an antibody ligand, would be beneficial for the purification and manufacturing procedure.  In addition to AAVs and LVs, baculoviral vectors and foamy viral vectors show great potential in a long-term perspective but they only have been researched in preclinical studies. Moreover, herpes simplex viral vectors and adenoviral vectors show potential in cancer treatments or as vaccines rather than in augmentation gene therapy.